<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962919</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 1818</org_study_id>
    <nct_id>NCT04962919</nct_id>
  </id_info>
  <brief_title>Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.</brief_title>
  <acronym>LACOG 1818</acronym>
  <official_title>Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of&#xD;
      individual characteristics and modalities of treatment in different national health&#xD;
      institutions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Describe cause-specific survival in patients with castration-resistant prostate cancer in different institutions in Brazil.</measure>
    <time_frame>December of 2017</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the sociodemographic characteristics of patients with castration-resistant metastatic prostate cancer in Brazil;</measure>
    <time_frame>December of 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe comorbidities of patients with castration-resistant metastatic prostate cancer in Brazil;</measure>
    <time_frame>December of 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the clinicopathological characteristics of patients with metastatic castration-resistant prostate cancer in Brazil;</measure>
    <time_frame>December of 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare overall survival among patients with castration-resistant metastatic prostate cancer treated in the SUS and in the private network;</measure>
    <time_frame>December of 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the treatments performed by patients with castration-resistant metastatic prostate cancer in the SUS and in the private network;</measure>
    <time_frame>December of 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the rates of skeletal-related complications</measure>
    <time_frame>December of 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the rate of admissions</measure>
    <time_frame>December of 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the number of lines of treatment that patients have undergone</measure>
    <time_frame>December of 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the presence or absence of treatments bone-directed</measure>
    <time_frame>December of 2017</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">590</enrollment>
  <condition>Prostatic Neoplasms, Castration-Resistant</condition>
  <arm_group>
    <arm_group_label>Public institution</arm_group_label>
    <description>Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Private institution</arm_group_label>
    <description>Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period&#xD;
        between January 2014 and December 2017.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period&#xD;
             between January 2014 and December 2017.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of localized or locally advanced or metastatic disease sensitive to&#xD;
             castration;&#xD;
&#xD;
          -  Patients with medical records filled with incomplete data that make it impossible to&#xD;
             evaluate the treatment received.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fernando Maluf, MD</last_name>
    <phone>+55 11 3505 6612</phone>
    <email>maluffc@uol.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gustavo Werutsky, MD</last_name>
    <phone>+55 51 33845334</phone>
    <email>gustavo.werutsky@lacog.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CPO Pucrs</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André Fay</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sírio Libanês</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diogo Bastos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A Real e Benemérita Associação Portuguesa de Beneficência</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01323-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Maluf, MD</last_name>
      <phone>+55 11 3505 6612</phone>
      <email>maluffc@uol.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Paulista de Oncologia</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrey Soares</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos e Pesquisas de Hematologia e Oncologia - CEPHO</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suelen Patricia dos Santos Martins, MD</last_name>
      <phone>4993-5491</phone>
      <email>suelen.martins@cepho.org.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina</name>
      <address>
        <city>São Paulo</city>
        <zip>(11) 2070-6000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Odebrecht Rocha, MD</last_name>
      <phone>55 11 22173766</phone>
      <email>robertoodebrecht@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de São Paulo - Hospital Central</name>
      <address>
        <city>São Paulo</city>
        <zip>01221-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deusdedit Cortez Vieira da Silva Neto, MD</last_name>
      <phone>+55 (11)98339-9974</phone>
      <email>vieiradasilva@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.C.Camargo Cancer Center</name>
      <address>
        <city>São Paulo</city>
        <zip>01525-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Augusto Rinck Júnior, MD</last_name>
      <phone>11 2189-5138</phone>
      <email>jose.rinck@accamargo.org.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Caffo O, Maines F, Rizzo M, Kinspergher S, Veccia A. Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions. Clin Interv Aging. 2016 Dec 22;12:19-28. doi: 10.2147/CIA.S98143. eCollection 2017. Review.</citation>
    <PMID>28053513</PMID>
  </reference>
  <reference>
    <citation>de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.</citation>
    <PMID>21612468</PMID>
  </reference>
  <reference>
    <citation>Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Oct 30;371(18):1755-6. doi: 10.1056/NEJMc1410239.</citation>
    <PMID>25354111</PMID>
  </reference>
  <reference>
    <citation>Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.</citation>
    <PMID>23863050</PMID>
  </reference>
  <reference>
    <citation>Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.</citation>
    <PMID>20818862</PMID>
  </reference>
  <reference>
    <citation>de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.</citation>
    <PMID>20888992</PMID>
  </reference>
  <reference>
    <citation>Tourinho-Barbosa RR, Pompeo AC, Glina S. Prostate cancer in Brazil and Latin America: epidemiology and screening. Int Braz J Urol. 2016 Nov-Dec;42(6):1081-1090. doi: 10.1590/S1677-5538.IBJU.2015.0690. Review.</citation>
    <PMID>27622278</PMID>
  </reference>
  <reference>
    <citation>Crawford ED, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol Oncol. 2017 May;35S:S1-S13. doi: 10.1016/j.urolonc.2017.01.020. Epub 2017 Mar 7. Review.</citation>
    <PMID>28283376</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

